ReviewFrontiers in pediatrics2019
Blood Biomarkers of Sensitization and Asthma.
Review in Frontiers in pediatrics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 37 citations in OpenAlex.
- Trial
- Evaluation of Total Serum IgE Level and Associated Factors in Asthmatic Patients at the University of Gondar Hospital, Northwest Ethiopia: A Comparative Cross-Sectional Study.Health science reports · 2026Article
- Characteristics of children with severe preschool asthma prior to starting the TIPP study.Frontiers in pediatrics · 2025Article
- Molecular Signatures of Aeroallergen Sensitization in Respiratory Allergy: A Comparative Study Across Climate-Matched Populations.International journal of molecular sciences · 2024Article
- Biomarkers Reflecting the Severity of Bronchial Asthma in Children.Journal of asthma and allergy · 2024Article
- Mechanistic and Therapeutic Approaches to Occupational Exposure-Associated Allergic and Non-Allergic Asthmatic Disease.Current allergy and asthma reports · 2023Review
- House Dust Mite Exposure through Human Milk and Dust: What Matters for Child Allergy Risk?Nutrients · 2022Article
- Asthma and Allergy: Unravelling a Tangled Relationship with a Focus on New Biomarkers and Treatment.International journal of molecular sciences · 2022Review
- Recurrent Severe Preschool Wheeze: From Prespecified Diagnostic Labels to Underlying Endotypes.American journal of respiratory and critical care medicine · 2021Article
- Resolving Clinical Phenotypes into Endotypes in Allergy: Molecular and Omics Approaches.Clinical reviews in allergy & immunology · 2021Review
- Club Cell Secreted Protein CC16: Potential Applications in Prognosis and Therapy for Pulmonary Diseases.Journal of clinical medicine · 2020Review
- Allergic Endotypes and Phenotypes of Asthma.The journal of allergy and clinical immunology. In practice · 2020Article
- Hospitalization, Asthma Phenotypes, and Readmission Rates in Pre-school Asthma.Frontiers in pediatrics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biomarkers are essential to determine different phenotypes of childhood asthma, and for the prediction of response to treatments. In young preschool children with asthma, aeroallergen sensitization, and blood eosinophil count of 300/μL or greater may identify those who can benefit from the daily use of inhaled corticosteroids (ICS). We propose that every preschool child who is considered for ICS treatment should have these two features measured as a minimum before a decision is made on the commencement of long-term preventive treatment. In practice, IgE-mediated sensitization should be considered as a quantifiable variable, i.e., we should use the titer of sIgE antibodies or the size of skin prick test response. A number of other blood biomarkers may prove useful (e.g., allergen-specific IgG/IgE antibody ratios amongst sensitized individuals, component-resolved diagnostics which measures sIgE response to a large number of allergenic molecules, assessment of immune responses to viruses, level of serum CC16, etc.), but it remains unclear whether these can be translated into clinically useful tests. Going forward, a more integrated approach which takes into account multiple domains of asthma, from the pattern of symptoms and blood biomarkers to genetic risk and lung function measures, is needed if we are to move toward a stratified approach to asthma management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.